Celgene's most recent trend suggests a bearish bias. One trading opportunity on Celgene is a Bear Call Spread using a strike $120.00 short call and a strike $130.00 long call offers a potential 18.2% return on risk over the next 28 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $120.00 by expiration. The full premium credit of $1.54 would be kept by the premium seller. The risk of $8.46 would be incurred if the stock rose above the $130.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Celgene is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Celgene is bearish.
The RSI indicator is at 24.04 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Broad Range of Clinical Data Evaluating Celgene Therapies to Be Presented at American Society of Clinical Oncology (ASCO)
Wed, 17 May 2017 21:41:00 +0000
Celgene Corporation today announced that data from a broad range of company-sponsored and investigator-initiated studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the American Society of Clinical Oncology Annual Meeting between June 2-6 in Chicago, Ill.
Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting
Wed, 17 May 2017 21:10:00 +0000
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.
Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract
Wed, 17 May 2017 21:02:00 +0000
The new enasidenib data — improved tumor response rate but shorter duration — were made public on Wednesday night in a research abstract.
Celgene leukemia drug extends survival in early stage trial
Wed, 17 May 2017 21:00:00 +0000
Nearly 20 percent of patients with an aggressive form of leukemia experienced complete remission along with prolonged survival from treatment with an experimental Celgene Corp drug, according to data from an early-stage study released on Wednesday. The drug, enasidenib, delivered high overall response rates in patients with acute myeloid leukemia (AML) whose disease had relapsed following prior treatments. Available data from 176 patients showed 40.3 percent responded to the treatment, with 19.3 percent achieving complete remission.
Cramer's lightning round: Buy this defense stock on fundamentals, not rumors
Tue, 16 May 2017 22:48:02 +0000
Jim Cramer rattles off his take on caller favorite stocks, including this defense play.
Related Posts
Also on Market Tamer…
Follow Us on Facebook